ライフサイエンスコーパス: EPD

1 EPD at 0.4 V in a solution of Au NPs prepared with a sho

2 EPD is based on ablative fractional laser or microneedle

3 EPD of OVA induced anti-OVA antibody titer at a level co

4 EPD of three modified oligodeoxynucleotides, a methylate

5 EPD of vaccinia virus encoding OVA induced significantly

6 EPD readings revealed average personal equivalent doses

7 EPD readings revealed average personal equivalent doses

8 EPD significantly improves the quality of spatial segmen

9 EPD use during TAVR remains infrequent and is associated

10 EPD use was associated with a reduction in disabling str

11 EPD use was associated with a similar adjusted risk of d

12 EPDs should enable an informed selection of products wit

13 EPDs were associated with a slightly higher incidence of

14 EPDs were used in 21.2% of saphenous vein grafts (median

15 a-EPD combines UVPD of negatively charged oligosaccharides

16 a-EPD is a hybrid activation method that uses ultraviolet

17 When adding complementary UVPD and a-EPD runs, we achieved 80% overall sequence coverage and

18 Both 193-nm UVPD and a-EPD yielded higher abundances and a larger array of prod

19 ion electron photodetachment dissociation (a-EPD) to yield high-quality MS/MS spectra.

20 This hybridized a-EPD approach was employed to characterize the structure

21 Notably, a-EPD affords extensive fragmentation throughout the backb

22 own as activated-electron photodetachment (a-EPD) affords less congested spectra than UVPD alone and

23 rgeted activated-electron photodetachment (a-EPD) tandem mass spectrometry to characterize LPS and LO

24 ted by activated-electron photodetachment (a-EPD), which uses 193-nm photons to create charge reduced

25 ), and activated electron photodetachment (a-EPD).

26 We benchmark the a-EPD method for top-down characterization of triacyl LOS

27 enzymes laccase and catalase by means of AC-EPD did not inhibit each other and carry out approximate

28 Additionally, EPD is used to pattern the growth of NU-1000 thin films

29 significant radiographic changes 5 wk after EPD in Veh or ZA animals.

30 reated versus nontreated ZA sites 5 wk after EPD.

31 patients of whom 53 389 (12.9%) received an EPD.

32 s performing >50% of TAVR procedures with an EPD and 72% performing no procedures with an EPD in the

33 EPD and 72% performing no procedures with an EPD in the last quarter of 2019.

34 ling with deposition of enzyme under ECD and EPD are considered including surface charge of enzyme, i

35 The main differences between ECD and EPD are described and highlighted in the sense to make i

36 Finally, the advantages of ECD and EPD in fabrication of miniature biosensor and biofuel ce

37 including the mannose-binding motifs EPN and EPD and the conserved WND motif that is required for bin

38 he association between procedural volume and EPD use.

39 stry data to examine the association between EPD use and a proxy for disabling stroke among transfemo

40 re claims to examine the association between EPD use and both procedural and long-term outcomes among

41 ust for confounding, the association between EPD use and clinical outcomes was evaluated using instru

42 The association between EPD use and CMS reimbursement was assessed using multiva

43 We evaluated the association between EPD use and disabling stroke using instrumental variable

44 able model, there was no association between EPD use and in-hospital stroke (adjusted relative risk,

45 tudy, we did not find an association between EPD use for TAVR and in-hospital stroke in our primary i

46 , MUFA, PUFA) were significantly affected by EPD x treatment interactions (P < 0.05).

47 isease, the progression date was predated by EPD by <or= 60 days in 31%, 61 to 180 days in 15%, and m

48 of baseline risk nor the benefit provided by EPDs has been well characterized.

49 LDV-C-EPD infected mice as efficiently as did LDV-P, but its l

50 d LDV-C of LDV-P by endpoint dilution (LDV-C-EPD).

51 In this contemporary cohort, EPDs were used more commonly among patients with high-ri

52 In conclusion, EPD represents a promising technology for needle-free, p

53 ted a new technology add-on payment to cover EPD use in October 2018.

54 d by sterile pustules, erosions, and crusts, EPD is difficult to treat and heals slowly.

55 pe, taken from the European Pollen Database (EPD) to produce a first synthesis of pan-European land c

56 ified from the Eukaryotic Promoter Database (EPD) for common polymorphisms.

57 e use of environmental product declarations (EPDs) of concrete and other construction materials is ga

58 Exceptional point degeneracies (EPD) of linear non-Hermitian systems have been recently

59 ar Nth-order exceptional point degeneracies (EPDs) where a small perturbation e 1 activates an inhere

60 micro-fractional epidermal powder delivery (EPD) is developed to facilitate skin vaccination and min

61 e spatial domain, edge-preserving denoising (EPD), which exploits the spatial relationships between R

62 Electrophoretic deposition (EPD) is used to assemble metal-organic framework (MOF) m

63 e size-dependent electrophoretic deposition (EPD) of citrate-stabilized Au nanoparticles (NPs) onto i

64 lass/ITO) by (1) electrophoretic deposition (EPD) of varying concentrations of 4 nm cit Au NPs and va

65 rates during the electrophoretic deposition (EPD) process.

66 of nHfO2@RGO and electrophoretic deposition (EPD) technique was used for its deposition onto ITO coat

67 sition (ECD) and electrophoretic deposition (EPD), in enzyme immobilization onto miniaturized electro

68 Erosive pustular dermatosis (EPD) is a rare condition that typically affects actinica

69 r cosmetic resurfacing, patients may develop EPD isolated to the face.

70 d cost, use of an embolic protection device (EPD) during transcatheter aortic valve replacement (TAVR

71 dation to use of embolic protection devices (EPD) for saphenous vein graft (SVG) intervention; howeve

72 with filter-type embolic protection devices (EPDs) and to determine its prognostic significance.

73 While cerebral embolic protection devices (EPDs) have been developed to mitigate this risk, data re

74 and outcomes of embolic protection devices (EPDs) in saphenous vein graft interventions.

75 Cerebral embolic protection devices (EPDs) were developed to mitigate the risk of stroke duri

76 ly by the use of embolic protection devices (EPDs), neither the level of baseline risk nor the benefi

77 construction of an empirical phase diagram (EPD).

78 rding to their estimated progeny difference (EPD) for marbling and blocked into high or low EPD group

79 ed ZA, and experimental periodontal disease (EPD) was induced around their second left maxillary mola

80 llowing early signal of progressive disease (EPD) criterion based on serum CA-125: for patients with

81 visualization using electrophoretic display (EPD).

82 alled electron photodetachment dissociation (EPD), results in abundant sequence ions in terms of w, z

83 x of EDTA-2- aminoethyl 2-pyridyl disulfide (EPD-Fe).

84 aling is mediated by a C-terminal EP domain (EPD) surface surrounding a cavity formed by the heterodi

85 Electronic personal dosimetry (EPD) was used for intraoperative occupational exposure (

86 The Encyclopedia of Proteome Dynamics (EPD) 'KinoViewer' is an interactive data visualization t

87 d via the Encyclopedia of Proteome Dynamics (EPD) - an open access, searchable online database.

88 Two-electrode EPD in aqueous solutions of Au NPs plus H2O2 reveal that

89 controlled trials and 1 registry evaluating EPDs in SVG percutaneous coronary intervention (n=3958 p

90 timate diagnosis most consistent with facial EPD.

91 essel revascularization; however, it favored EPD use in all-cause mortality and major adverse cardiov

92 calculations provide a robust estimation for EPD measurements.

93 distinguished from a blank solution even for EPD times up to 5 h.

94 le analysis with a site-level preference for EPD use as the instrument-a quasi-experimental approach

95 ational data, with site-level preference for EPD use within the same quarter of the procedure as the

96 romoted intramuscular fat deposition in high EPD bulls.

97 and dressing percentage, especially in high-EPD animals.

98 ling influenced dietary responses, with high-EPD bulls showing greater fat deposition and energy effi

99 There was wide variation in EPD use across hospitals, with 8% of sites performing >5

100 ust comparison based on the existing data in EPDs.

101 er TAVR volume was associated with increased EPD use (per 25 TAVRs; aOR, 1.15 [95% CI, 1.09-1.21]; P

102 ling bulls were classified into high and low EPD groups and assigned to five diets: (1) fine ground c

103 D) for marbling and blocked into high or low EPD groups.

104 king loss (P < 0.01), whereas those with low EPD showed higher protein (P < 0.01) and collagen conten

105 vated tissues, PAD4(R314A) and SAG101(M304R) EPD variants maintain interaction with EDS1 but lose ass

106 In summary, classification by marbling EPD allowed to demonstrate that genetic predisposition i

107 or of Nellore cattle with divergent marbling EPD.

108 Bulls with high marbling EPD fed HMC + CSFA exhibited greater intramuscular fat (

109 e of a newly synthesized electrode material, EPD-3D.

110 opportunities that can promote a meaningful EPD comparison for concrete products.

111 ysis using the propensity score-based model, EPD use was associated with 18% lower odds of in-hospita

112 Of 84 progression-free patients, nine EPDs were found.

113 0.7% among the EPD group and 0.9% in the no-EPD group.

114 metric steady-state - and displays nonlinear EPDs (NLEPDs) that can be employed for noise-resilient s

115 The novel EPD delivered more than 80% sulforhodamine b (SRB) and m

116 In subgroup analyses, the benefit of EPD was greater among those with versus without prior st

117 The exact cause of EPD is unknown, although trauma is an inciting factor.

118 ve a long-standing debate on the efficacy of EPD-sensing in active systems above self-oscillating thr

119 environmental footprint; hence, the issue of EPD comparability is highly relevant.

120 VR was associated with greater likelihood of EPD use in model 1.

121 ere was no significant change in the odds of EPD uptake before vs after institution of the CMS new te

122 ggests no apparent benefit in routine use of EPD during SVG intervention in the contemporary real-wor

123 The use of EPD during TAVR increased over time, reaching 28% of sit

124 valuate long-term outcomes in routine use of EPD, and meanwhile, current guideline recommendations on

125 The treatment benefit of EPDs was preserved across all categories of risk as cate

126 Given these results, the impact of EPDs during TAVR remains unclear.

127 consistent treatment benefit with the use of EPDs across the range of patients tested in randomized t

128 nwhile, current guideline recommendations on EPD use should be revisited.

129 residues (Arg314 and Lys380) lining the PAD4 EPD cavity that are essential for EDS1-PAD4-mediated pat

130 form represents the application of low-power EPD in epidermal sweat sensor, evaluated through CIELAB-

131 ealing wounds following ablative procedures, EPD is challenging to treat and may require the use of a

132 via the Electrophoresis Deposition Process (EPD).

133 Based on the published EPDs, we suggest a more comprehensive water consumption

134 While reducing local reactogenicity, EPD of OVA/LPS/CpG and BCG vaccine generated a comparabl

135 A method of repeated EPD and heat treatment above melting point were employed

136 in the absence or presence of rosiglitazone, EPD was induced for 5 wk, and the MRONJ burden was asses

137 ective studies are needed to support routine EPD use.

138 of similar but non-identical PAD4 and SAG101 EPD surfaces to specific EDS1 dimer protein interactions

139 y equivalent Met304 and Arg373 at the SAG101 EPD cavity are required for EDS1-SAG101 promotion of ETI

140 riability as well as a supply-chain-specific EPD creation can help move toward a robust comparison ba

141 udy to date, among patients undergoing TAVR, EPD use was associated with a small, borderline signific

142 hese findings provide credible evidence that EPDs benefit patients undergoing TAVR.

143 The EPD showed that the DB fusion in OPOE is most stable at

144 hospital disabling stroke was 0.7% among the EPD group and 0.9% in the no-EPD group.

145 Overall, 135 patients met the EPD criterion.

146 PATIENTS AND METHODS The EPD criterion was tested on Southwest Oncology Group tri

147 wer is currently only accessible through the EPD, it is open access and can be used either to view in

148 ms of Au) and a constant 1 min ECD time, the EPD time required to achieve a maximum ASV signal increa

149 Here we investigated whether the EPDs of PAD4 and SAG101 contribute to EDS1 dimer functio

150 tection With Sentinel During Transcatheter), EPD use did not reduce periprocedural stroke (primary st

151 arotid artery intervention using filter-type EPDs, we have observed cases in which there is angiograp

152 cious arrangement of active elements (unlike EPD platforms), and, if chosen, can be cavity free.

153 Using EPD times of 30 min and increasing the ECD time to 5-10

154 TrFE) films on stainless steel springs using EPD process.

155 rwent 453 carotid artery interventions using EPDs.

156 oncentrations of 4 nm cit Au NPs and varying EPD time (30 s to 5 h), (2) seeded electrochemical depos

157 ng the Encrypted Pixel Difference (SRDH-VRAE-EPD) method, which combines homomorphic encryption and e

158 When EPD-Fe was used to modify residue Cys16 in C5 protein, h

159 andomized, controlled trials to test whether EPDs provide meaningful clinical benefit for patients un

160 ents were women in their 50s or 60s for whom EPD was deemed to be the best diagnosis, after infection

161 Patient characteristics associated with EPD use included prior stroke (adjusted odds ratio [aOR]

162 to be the predominant factor associated with EPD use.

163 3) comparing SVG intervention performed with EPD (n=11 506) and without EPD (n=41 387) were included.

164 t the sites, 6012 (7.1%) underwent TAVR with EPD.

165 Slow-flow during carotid intervention with EPDs is a frequent event that is associated with an exce

166 on performed with EPD (n=11 506) and without EPD (n=41 387) were included.

167 ization in SVG intervention with and without EPD.